Delpharm continues its growth in Europe with the acquisition of state-of-the-art drug production facilities in the Netherlands, from Astellas.

Published on

The site, fully equipped with state-of-the-art technologies, is located in the Netherlands in a 31,600 square meter unit created in 1994.

Nowadays, this manufacturing site employs 410 qualified personnel who contribute to the production of solid dosage forms, such as tablets, capsules and pellets. The site produces more than 40 million finished products packaged annually.

Meppel site holds most of the quality authorisations for exporting medicines to the world, including the FDA certification for the United States. The site is also committed to eco-responsibility with the ISO 14001 and 45001 certifications.

“We are delighted to further expand our operations in the Netherland with this 3rd site. Thanks to the Meppel site acquisition, we will strengthen our position in the Netherlands where Delpharm already owns one manufacturing site in Bladel and an injectable drug development centre in Leiden”, says Nicolas Ragot, Managing Director of Delpharm.

Delpharm is pleased to welcome the Meppel team on board and looks forward to working with them to provide its customers the strong solid forms expertise of the CDMO.